All change at Erasca with new pipeline and financing

Precision oncology company Erasca (Nasdaq: ERAS), which is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, opened trading 8% higher Friday.

This followed news that the San Diego-based company had entered into exclusive license agreements for two pre-clinical RAS programs, one being a potential best-in-class pan-RAS molecular glue, ERAS-0015, and the other a potential first-in-class pan-KRAS inhibitor, ERAS-4001.

"Further focusing our resources will allow us to advance the programs with the highest probability of success"Both are highly potent, orally bioavailable molecules with complementary RAS inhibitory mechanisms that have the potential to address unmet needs in nearly 2.7 million patients who are diagnosed annually globally with RAS-mutant tumors, of which more than 2.2 million are diagnosed with KRAS-mutant tumors.